ESBATech News
Most Popular ESBATech Story
Alcon scoops up ESBATech in $589M buyout
Alcon (ACL) is slapping down $150 million to scoop up Switzerland's ESBATech while setting aside $439 million more for a schedule of milestone payments. For Alcon, the deal delivers antibody fragment... Read more...
Latest Headlines
- September 14, 2009
- August 7, 2008
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
